Journal News

From the journals: JLR

Meric Ozturk
Oct. 6, 2023

Can DHA curb Alzheimer’s memory loss? The role of sex in regulating heat. A tale of two proteins in cardiovascular disease. Read about papers on these topics recently published in the Journal of Lipid Research.

Can DHA curb Alzheimer’s memory loss?

A major consequence of Alzheimer's disease is memory loss. The area of the brain called the entorhinal cortex, or EC, is a hub for memory, navigation and time perception. In Alzheimer's, decreased EC thickness correlates with memory impairment. In the past, researchers have noticed that docosahexaenoic acid, or DHA, supplements can increase thickness and repair these cognitive abilities in humans. A high DHA level correlates with low levels of brain inflammation.

Carrying an apolipoprotein ε allele 4, or APOE4, gene is also a marker for Alzheimer’s. This gene produces the ApoE4 enzyme, which impairs metabolism of polyunsaturated fatty acids such as DHA. Researchers have reported that increased ApoE4 activity results in decreased DHA in plasma and cerebrospinal fluid, or CSF. They have hypothesized that DHA circulation is provided by lipid species such as phosphatidylcholines, cholesteryl esters and triglycerides, or TGs, and that ApoE4 affects metabolism of these lipids and circulation of DHA.

Researchers still did not know which lipid species is important for DHA and which is affected by ApoE4, however. Mikaila Ann Bantugan, Haotian Xian and Victoria Solomon of the University of Southern California and a research team investigated this question and published their study in the Journal of Lipid Research.

The transport of DHA on plasma TGs is significant in Alzheimer’s. The team observed that APOE4 had the strongest effects on the DHA containing TG lipids and that increased DHA within TGs was suppressed in APOE4 carriers compared to noncarriers in CSF and plasma. Also, supplementing with algal TG-based DHA for six months increased EC thickness in human study participants independent of ApoE4 presence.

This study used a small sample and did not consider body mass index and sex. However, their findings indicate that DHA supplements may be an alternative treatment for memory loss in Alzheimer’s disease and provide another approach to understanding the role of ApoE4 in the disease.

The role of sex in regulating heat

Thermogenesis, or heat production, can be regulated by the hypothalamus and is an important component of regulators of energy homeostasis. Reduced thermogenesis cuts energy consumption during energy deficiency, known as negative energy balance. In the hypothalamus, pro-opiomelanocortin, or POMC, neurons are essential to regulate the negative energy balance and regulate lipogenesis in brown and white adipose tissues. Toll-like receptor 4, or TLR4, also regulates lipogenesis; a part of its signal is produced in the hypothalamus, and activation of this signal inhibits the anorexia signal that triggers lipid production. Although POMC cells and TLR4 are associated with the anorexia signal, researchers have not yet proved a POMC–TLR4 relationship.

Yongxiang Li, Shuqing Zhu and a team of scientists in China investigated this question and published their findings in the Journal of Lipid Research.

The group genetically altered mice with POMC cells lacking TLR4 receptors to observe metabolic changes. In the male mice, this affected lipogenesis in brown adipose tissue and increased thermogenesis, resulting in reduced body weight. In female mice, deleting TLR4 in POMC neurons decreased energy expenditure and increased body weight, which affects lipolysis of white adipose tissue. These sex-dependent effects indicate that sex should be considered when developing treatments for obesity.

A tale of two proteins in cardiovascular disease

Serum amyloid A, or SAA, protein is a marker of inflammation linked to cardiovascular disease, or CVD, such as atherosclerosis in humans. In mice, SAA promotes development of atherosclerosis. One study has shown that SAA is elevated in obese mice that are genetically altered to be deficient in apolipoprotein E, or ApoE, an enzyme critical to lipid metabolism and cholesterol circulation.

SAA is carried by high-density lipoprotein, or HDL, in the blood. Researchers have reported that binding of cholesteryl ester transfer protein, or CETP, to HDL results in lipid-free SAA and leads to the transfer of SAA from HDL to other cholesterols. However, no one has yet shown whether SAA contributes to the pathologic effect of CETP in mice. Ailing Ji at the University of Kentucky and a group of researchers published their study on this question in the Journal of Lipid Research.

To investigate whether SAA contributes to the pro-atherogenic effect of CETP, the group generated what they called “only apoE lacking mice” as well as apoE-lacking mice deficient in SAA with and without expressing CETP. They found that the effect of CETP was SAA dependent; remodeling of normal HDL lacking SAA did not stimulate CETP-dependent inflammation. However, the pathologic effect of SAA was increased by CETP expression. The scientists state that CETP inhibition may have therapeutic benefits in patients with high SAA levels.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Meric Ozturk

Meric Ozturk is a Ph.D. student in biochemistry at Iowa State University and an ASBMB Today volunteer contributor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

What’s in a diagnosis?
Essay

What’s in a diagnosis?

Sept. 4, 2025

When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Annual Meeting

Peer through a window to the future of science

Sept. 3, 2025

Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
Journal News

Glow-based assay sheds light on disease-causing mutations

Sept. 2, 2025

University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.

How signals shape DNA via gene regulation
Journal News

How signals shape DNA via gene regulation

Aug. 19, 2025

A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent MCP paper.

A game changer in cancer kinase target profiling
Journal News

A game changer in cancer kinase target profiling

Aug. 19, 2025

A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent MCP paper.

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.